Tuesday, November 22, 2022 9:38:24 PM
https://www.linkedin.com/company/cbdxfund/about/
Cannabinoid Biosciences, Inc. logo
Cannabinoid Biosciences, Inc.
CBDxFUNDis the first female-controlled CBD IPO in the U.S. & Canada. Learn more about CBD investment opportunities.
Biotechnology Research Los Angeles, CA 6,073 followers
See all 3 employees on LinkedIn
Follow
Visit website
More
Home
About
Posts
Jobs
People
Videos
Overview
Cannabinoid Biosciences, Inc. (“CBDZ”) is a biopharmaceutical company, which intends to engage in the discovery, development and commercialization of cures and novel therapeutics from proprietary cannabinoid, cannabidiol, endocannabinoids, phytocannabinoids, and synthetic cannabinoids product platform suitable for specific treatments in a broad range of disease areas.
Our business is divided into four segments namely:
1. Biopharmaceutical Research and Development;
2. Investments into legal-cannabis businesses and deriving value from rollup/consolidation events that leads to IPO in US or Canada;
3. Financial products in form of asset-backed loans, business property mortgages and other financial products to qualified individuals/businesses in the legal-cannabis businesses; and
4. Professional services including top-level financial reporting, Accounting
Two of our business units are in flux and have investment opportunities that we want to capitalize upon immediately:
• Rollup and Consolidation: Investments into legal-cannabis businesses and deriving value from rollup/consolidation events that leads to IPO in US or Canada; and
• Financial products in form of asset-backed loans, business property mortgages and other financial products to qualified individuals/businesses in the legal-cannabis businesses.
CBDZ is raising $125 million with Reg A+ ($50 million) and Reg. D 506 (c) ($75 million). The Company had filed the required filings with the SEC and is waiting for their go-ahead for the Reg. A+. CBDZ has agreed to rollup 10 dispensaries with $54 million in annual revenue. These rollup will IPO on the NASDAQ or NYSE and Canadian Securities Exchange (CSE) via Reg. A+, which is already filed with the SEC. Once our Reg A+ is qualified, CBDZ will be listed on the NASDAQ or NYSE. A $1,000 invested at this ground floor could fetch up to $21,500 based on what the NASDAQ and NYSE market-participants sale-to-market cap multiples for rollup/consolidated Cannabis business.
Website
http://cbdxfund.com
Industry
Biotechnology Research
Company size
11-50 employees
3 on LinkedIn
Includes members with current employer listed as Cannabinoid Biosciences, Inc., including part-time roles.
Headquarters
Los Angeles, CA
Founded
2014
Locations (1)
Primary
Wilshire, Los Angeles
3699 WILSHIRE BLVD.,, STE 610, Los Angeles, CA 90010, US
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM